Cabaletta Bio (CABA) Research & Development (2018 - 2025)
Cabaletta Bio's quarterly Research & Development came in at $36.2 million in Q4 2025, up 57.37% year-on-year from $23.0 million in Q4 2024, and down 9.12% quarter-over-quarter from $39.8 million in Q3 2025.
Cabaletta Bio has reported Research & Development for 8 years, with the latest figure at $36.2 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 57.37% year-over-year to $36.2 million; the trailing twelve-month figure through Dec 2025 stood at $142.7 million (up 50.71% YoY), and the FY2025 full-year result was $142.7 million, up 46.78% from the prior year.
- Research & Development for Q4 2025 stood at $36.2 million, down from $39.8 million in the prior quarter.
- The five-year high for Research & Development was $39.8 million in Q3 2025, with the low at $6.6 million in Q1 2021.
- Average Research & Development over 5 years is $18.2 million, with a median of $13.1 million recorded in 2023.
- Year-over-year, Research & Development grew 0.58% in 2022 and jumped 98.58% in 2024.
- Tracing CABA's Research & Development over 5 years: stood at $9.9 million in 2021, then gained by 25.01% to $12.4 million in 2022, then soared by 40.36% to $17.4 million in 2023, then jumped by 32.15% to $23.0 million in 2024, then soared by 57.37% to $36.2 million in 2025.
- The last three Research & Development figures came in at $36.2 million (Q4 2025), $39.8 million (Q3 2025), and $37.6 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | 36.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 36.19 Mn |
| Sep 30, 2025 | 39.82 Mn |
| Jun 30, 2025 | 37.64 Mn |
| Mar 31, 2025 | 29.02 Mn |
| Dec 31, 2024 | 23.00 Mn |
| Sep 30, 2024 | 26.29 Mn |
| Jun 30, 2024 | 23.43 Mn |
| Mar 31, 2024 | 21.95 Mn |
| Dec 31, 2023 | 17.41 Mn |
| Sep 30, 2023 | 13.79 Mn |
| Jun 30, 2023 | 11.80 Mn |
| Mar 31, 2023 | 12.44 Mn |
| Dec 31, 2022 | 12.40 Mn |
| Sep 30, 2022 | 8.22 Mn |
| Jun 30, 2022 | 9.51 Mn |
| Mar 31, 2022 | 9.17 Mn |
| Dec 31, 2021 | 9.92 Mn |
| Sep 30, 2021 | 8.17 Mn |
| Jun 30, 2021 | 7.85 Mn |
| Mar 31, 2021 | 6.56 Mn |
| Dec 31, 2020 | 5.78 Mn |
| Sep 30, 2020 | 5.65 Mn |
| Jun 30, 2020 | 5.33 Mn |
| Mar 31, 2020 | 4.62 Mn |
| Dec 31, 2019 | 3.03 Mn |
| Sep 30, 2019 | 3.22 Mn |
| Jun 30, 2019 | 2.66 Mn |
| Mar 31, 2019 | 2.76 Mn |
| Dec 31, 2018 | 1.24 Mn |
| Sep 30, 2018 | 2.59 Mn |